AstraZeneca plc (ADR) (NYSE:AZN)

Restructuring will cut fat while they restock their drug pipeline, and should eventually allow them to continue raising their dividend.

High yield strategy: TMFHighYield says to look for "high dividend payers from the S&P 500 from diverse sectors, relatively low debt, and a history of increasing dividend payments." This is my Health Care pick.
$46.88

Product offering

New CEO

SP Low PE

Meets my metrics of low PE, high yield, eps, beta, roe and net profit. And 10 percent below 52-week high.

5star
good div
good cash flow
esp growth 24.00
new cancer treatment in the works

It probably will because of many reasons. One is timeline. At the long run, this will outrun it's competitors in the market.

DIVIDEND/ROE MONSTER

Very low P/E.

Selling at a discount. I would like to see some new drugs come through to keep the high ROIC going...

low p/e high div yield

Very cheap stock, with under 6 p/e, but still earning incredible returns on capital. Has been hit too hard among the pharmaceutical firms. Great contrarian play, with a great dividend Yield of over 6%.

FDL1

http://seekingalpha.com/article/317243-the-5-yield-solution

Note to self: "actually" in at 44.ish in this week - late Fool-tracking. Sad disclosure!

AZN's the maker of Seroquel and Mysoline, two really far out psychiatric neurological drugs. So I hear.

12/13

buybacks...great yield.... 10% off 52 week low

Long Term Outperform.